Skip to content
menu
Home
Algemene informatie
Registratie
Programma
Sponsors
Contact
Programma overzicht
Print programma
Vrijdag 17 januari
Vorige dag
Volgende dag
Coffee break
Tijd: 15:30 - 15:35 CET
✕
Drinks
Tijd: 17:00 - 17:05 CET
✕
Who can we spare immunotherapy? Biomarkers
Tijd: 16:30 - 16:35 CET
Prof. dr. Alessandra Curioni, University Freiburg, Germany
✕
Targeted treatment in early stage NSCLC
Tijd: 15:00 - 15:05 CET
No avatar
Dr. Suresh Ramalingan, Emory University, United States
✕
First line options for EGFR+ NSCLC
Tijd: 14:30 - 14:35 CET
No avatar
Prof. dr. David Planchard, Thoracic oncologist, Gustave Roussy
✕
Lunch
Tijd: 12:45 - 12:50 CET
✕
What to do with all these data?
Tijd: 10:40 - 10:45 CET
✕
Immunotherapy and comorbidities, the side effect treatment beyond steroids
Tijd: 16:00 - 16:05 CET
Prof. Jarushka Naidoo, Medical Oncologist, Beaumont Hospital And RCSI University
✕
Are you NUTs? Challenges and opportunities for the pathologist in tumors in the chest
Tijd: 12:00 - 12:05 CET
No avatar
Dr. Danielle Cohen, patholoog, LUMC
Dr. Gerrina Ruiter, Longarts, AVL
✕
Prevention of vaping. The facts and the struggle.
Tijd: 14:00 - 14:05 CET
No avatar
Frank Borm, Longarts, LUMC
✕
Coffee break
Tijd: 11:00 - 11:05 CET
✕
Surgery is key in the treatment of stage III NSCLC.
Tijd: 10:20 - 10:25 CET
No avatar
Prof. Eric Lim, Brompton, London
✕
Radiotherapy is key in the treatment of stage III NSCLC
Tijd: 10:00 - 10:05 CET
No avatar
Matthias Guckenberger, University Hospital, Zurich
✕
Neo-adjuvant therapy: lessons from other malignancies (than NSCLC)
Tijd: 11:30 - 11:35 CET
Dr. Myrjam Chalabi, Internist-oncoloog, NKI-AVL
✕
The Legend of the RECIST criteria: Will Artificial Intelligence Take Over Tumor Measurement?
Tijd: 09:30 - 09:35 CET
No avatar
Illaa Smesseim, longarts en arts-onderzoeker, NKI-AVL
No avatar
Kevin Groot Lipman, NKI-AVL
✕
Welcome
Tijd: 09:00 - 09:05 CET
✕
Home
›
Programma